This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Dec 19;374(9707):2029-2030.

doi: 10.1016/S0140-6736(09)62097-3. Epub 2009 Dec 10.

Fighting overtreatment in adjuvant breast cancer therapy

Michael Gnant¹, Guenther G Steger²

Affiliations

Affiliations

¹ Medical University of Vienna, A-1090 Vienna, Austria. Electronic address: michael.gnant@meduniwien.ac.at.
² Medical University of Vienna, A-1090 Vienna, Austria.

PMID: 20004965
DOI: 10.1016/S0140-6736(09)62097-3

Comment

Fighting overtreatment in adjuvant breast cancer therapy

Michael Gnant et al. Lancet. 2009.

. 2009 Dec 19;374(9707):2029-2030.

doi: 10.1016/S0140-6736(09)62097-3. Epub 2009 Dec 10.

Authors

Michael Gnant¹, Guenther G Steger²

Affiliations

¹ Medical University of Vienna, A-1090 Vienna, Austria. Electronic address: michael.gnant@meduniwien.ac.at.
² Medical University of Vienna, A-1090 Vienna, Austria.

PMID: 20004965
DOI: 10.1016/S0140-6736(09)62097-3

No abstract available

PubMed Disclaimer

Comment on

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK; Breast Cancer Intergroup of North America. Albain KS, et al. Lancet. 2009 Dec 19;374(9707):2055-2063. doi: 10.1016/S0140-6736(09)61523-3. Epub 2009 Dec 10. Lancet. 2009. PMID: 20004966 Free PMC article. Clinical Trial.
Breast cancer management is improving.
The Lancet. The Lancet. Lancet. 2009 Dec 19;374(9707):2028. doi: 10.1016/S0140-6736(09)62136-X. Lancet. 2009. PMID: 20109815 No abstract available.

Similar articles

Over-using chemotherapy in the adjuvant setting.
Curigliano G, Criscitiello C, Esposito A, Pruneri G. Curigliano G, et al. Breast. 2017 Feb;31:303-308. doi: 10.1016/j.breast.2016.11.011. Epub 2016 Nov 17. Breast. 2017. PMID: 27866835
Side effects of adjuvant treatment of breast cancer.
Shapiro CL, Recht A. Shapiro CL, et al. N Engl J Med. 2001 Jun 28;344(26):1997-2008. doi: 10.1056/NEJM200106283442607. N Engl J Med. 2001. PMID: 11430330 Review. No abstract available.
How does adjuvant chemotherapy affect menopausal symptoms, sexual function, and quality of life after breast cancer?
Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M. Marino JL, et al. Menopause. 2016 Sep;23(9):1000-8. doi: 10.1097/GME.0000000000000664. Menopause. 2016. PMID: 27272225
Reduced side-effects of adjuvant hormone therapy in breast cancer patients by complementary medicine.
Uhlenbruck G, VAN Leendert R, Schneider B, Beuth J. Uhlenbruck G, et al. In Vivo. 2010 Sep-Oct;24(5):799-802. In Vivo. 2010. PMID: 20952754 Clinical Trial.
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.
Bines J, Oleske DM, Cobleigh MA. Bines J, et al. J Clin Oncol. 1996 May;14(5):1718-29. doi: 10.1200/JCO.1996.14.5.1718. J Clin Oncol. 1996. PMID: 8622093 Review.

See all similar articles

Cited by

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Dubsky P, et al. Ann Oncol. 2013 Mar;24(3):640-7. doi: 10.1093/annonc/mds334. Epub 2012 Oct 3. Ann Oncol. 2013. PMID: 23035151 Free PMC article.
The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients.
Pachmann K, Schuster S. Pachmann K, et al. Cancers (Basel). 2018 Oct 29;10(11):407. doi: 10.3390/cancers10110407. Cancers (Basel). 2018. PMID: 30380648 Free PMC article.
Modern therapeutic concepts of early breast cancer.
Gnant M. Gnant M. Breast Care (Basel). 2014 May;9(2):85-6. doi: 10.1159/000362528. Breast Care (Basel). 2014. PMID: 24944549 Free PMC article. No abstract available.
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.
Laible M, Hartmann K, Gürtler C, Anzeneder T, Wirtz R, Weber S, Keller T, Sahin U, Rees M, Ramaswamy A. Laible M, et al. BMC Cancer. 2019 Jul 15;19(1):694. doi: 10.1186/s12885-019-5890-z. BMC Cancer. 2019. PMID: 31307414 Free PMC article.
Guidelines: usefulness and limitations.
Gnant M. Gnant M. Breast Care (Basel). 2013 Jun;8(3):172-3. doi: 10.1159/000353791. Breast Care (Basel). 2013. PMID: 24415965 Free PMC article. No abstract available.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information